According to the content of the abstracts, 64 publications were excluded because 8 of them were reviews or meta-analyses, 47 were not related to bladder cancer, 4 were not related to our genes of interest (TP53/MDM2), 2 did not evaluate polymorphisms of interest, and 3 were not case-control studies. This evidence concerns the gene MDM2 and urinary bladder carcinoma.